CyberKnife Market Size Analysis:

The CyberKnife Market Size was valued at USD 542.14 million in 2023 and is expected to reach USD 2340.47 million by 2032, growing at a CAGR of 17.67% over the forecast period of 2024-2032. This report identifies the occurrence and prevalence of conditions treated using CyberKnife, such as cancer and neurological disease, which generate demand for high-precision radiation therapy. This study analyzes trends in CyberKnife adoption and usage by region with the push provided by the innovation in stereotactic radiosurgery (SRS) technology as well as improving physician acceptance. Moreover, cost and pricing trends of CyberKnife systems are examined, with installation costs, maintenance costs, and reimbursement policies being key drivers of accessibility. Regional regulatory and policy trends affecting CyberKnife adoption are also examined in the report, with government approvals and healthcare infrastructure development affecting market penetration. In addition, healthcare expenditures on CyberKnife treatment are also region-dependent, with varying funding sources like government-supported programs, private insurance, and out-of-pocket spending influencing patient accessibility.

The U.S. CyberKnife Market was valued at USD 160.99 million in 2023 and is expected to reach USD 730.98 million by 2032, growing at a CAGR of 18.33% over the forecast period of 2024-2032. In the United States, the CyberKnife market is growing as a result of increased cancer prevalence, expanding insurance coverage for non-surgical procedures, and rising investments in sophisticated radiotherapy technologies to improve treatment accuracy and patient outcomes.

CyberKnife Market Dynamics

Drivers

• The rising prevalence of cancer and neurological disorders, increasing adoption of non-invasive treatment options, and technological advancements in robotic radiosurgery.

With more than 19.3 million new cancer diagnoses occurring worldwide in 2023, the need for accurate, focused treatment options such as CyberKnife has grown dramatically. Unlike traditional radiotherapy, CyberKnife is capable of delivering sub-millimeter precision without the need for invasive procedures, minimizing patient recovery time and hospitalization. Plus, its capability to monitor tumor motion in real-time positions it as extremely effective for treating tumors in the lungs, prostate, and spine. The increased popularity of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) as alternatives to conventional surgery is also propelling market growth. Advances like artificial intelligence (AI)-based treatment planning and imaging modality integration have enhanced treatment accuracy and workflow efficiency. In addition, rising healthcare spending and favorable reimbursement policies in developed nations favor the adoption of CyberKnife. Top medical facilities and research organizations are constantly investigating broader uses, such as the treatment of vascular malformations and functional neurological disorders. With the aging population, which has a higher risk of cancer and neurodegenerative diseases, demand for efficient and minimally invasive radiosurgery products keeps growing, placing CyberKnife at the forefront of the changing radiotherapy landscape.

Restraints

• The CyberKnife market faces significant restraints, including high installation and maintenance costs, limited accessibility in developing regions, and reimbursement challenges.

The initial investment of a CyberKnife system is between USD 4 and 6 million, and this makes the technology a big investment for healthcare institutions, particularly small hospitals and outpatient facilities. There are also yearly maintenance and operating expenses that add to the load of institutions, thus hindering extensive application. The specialized training and expertise needed also limit the accessibility, as not every healthcare facility can afford or keep up with the technology. Additionally, reimbursement policies differ geographically, with some insurance companies providing partial or no coverage for CyberKnife treatment, which is costly to patients. In contrast to traditional radiotherapy, which is reimbursed by most national health systems, the high cost of treatment by CyberKnife (USD 30,000 to USD 50,000 per patient in certain instances) restricts its affordability. Regulatory challenges also hinder adoption since clearance procedures for novel applications can span years. The absence of familiarity and clinical experience in certain developing markets has further led to the sluggish acceptance of CyberKnife as an optimal treatment option. Although the technology provides invaluable advantages, such cost and logistics issues continue to hold back its extensive deployment worldwide within healthcare systems.

Opportunities

• The CyberKnife market presents vast opportunities, including expansion into emerging economies, increased application in non-oncology treatments, and AI-driven innovations.

With the improvement of the global healthcare infrastructure, emerging economies are seeing more investment in sophisticated medical technologies. Governments and private healthcare providers in nations such as India, China, and Brazil are emphasizing upgrading cancer treatment facilities, generating demand for CyberKnife installations. A further significant opportunity exists in the move beyond oncology, with CyberKnife increasingly being investigated for the treatment of vascular malformations, epilepsy, and movement disorders such as Parkinson's disease. Clinical trials are also examining its promise in the treatment of cardiac arrhythmias and trigeminal neuralgia, further expanding its market potential. In addition, artificial intelligence (AI) incorporation in the planning and automation of workflow is making processes more efficient, decreasing planning time, and enhancing accuracy. Vendors such as Accuray are putting money into AI-based imaging and motion-tracking technology to make CyberKnife more effective. Partnerships among healthcare providers and technology companies are driving product development of new types, such as hybrid solutions incorporating CyberKnife along with other radiation therapy modalities. Increasing focus on patient-oriented care and preferences for minimally invasive therapies also is increasing demand for CyberKnife as an acceptable alternative to surgery, with big growth prospects for the future years.

Challenges

• The competition from alternative treatment modalities, the need for continuous technological advancements, and long approval cycles for new applications.

Though CyberKnife is highly precise, traditional radiotherapy methods such as proton therapy, Gamma Knife, and linear accelerators (LINACs) still vie for the radiosurgery market, with some hospitals opting for tried-and-tested technologies because they are cheaper and have wider insurance coverage. In addition, CyberKnife needs regular software and hardware upgrades, which means constant investment in R&D. Without constant innovation, the system will become obsolete against newer radiosurgery options. Another major issue is delays in regulatory approvals, as clearance for additional indications takes years. For instance, the FDA and European authorities demand long clinical trials before they approve CyberKnife for non-oncology use, which hinders market growth. Moreover, training of the workforce and skill shortages are obstacles since CyberKnife demands highly skilled radiation oncologists and physicists, hindering its use in areas lacking proper medical talent. Patient resistance based on inadequate awareness and perceived high expense is also a continued obstacle. As promising as the technology is, overcoming these will be necessary if CyberKnife is to continue its growth and win wider acceptance over the coming years.

CyberKnife Market Segmentation Analysis

By Application

Cancer dominated the CyberKnife market in 2023, with a 40.8% share. Its prevalence, rising use of non-invasive treatment approaches, and heightened awareness of stereotactic radiosurgery (SRS) helped lead its market dominance. CyberKnife's accuracy in the treatment of tumors in delicate regions, like the brain, spine, and prostate, has earned it the trust of oncologists as the go-to treatment option, cementing its leadership.

Vascular malformation is the most rapidly growing application segment, spurred by new developments in CyberKnife technology and rising clinical uptake. The precision with which the system delivers high doses of radiation has improved treatment results for arteriovenous malformations (AVMs) and other vascular abnormalities, fueling a new wave of demand. The increasing familiarity with CyberKnife as a non-invasive alternative to surgery for these conditions is a primary driver of this explosive growth.

By End Use

Hospitals dominated the CyberKnife market in 2023, with a share of 47.2%, because they experienced greater patient influx, sophisticated facilities, and exposure to specialized radiation oncology facilities. The availability of multidisciplinary teams, reimbursement, and the capacity to treat complicated cases have established hospitals as the core centers for CyberKnife treatments. Government grants and hospital-based clinical trials have also strengthened their position in the market.

Outpatient centers are the most rapidly expanding end-use segment, helped by the rising demand for minimally invasive treatment and affordable care settings. Being able to treat with CyberKnife in an outpatient environment without lengthy hospital stays has fueled demand. The trend toward ambulatory care, combined with technology that supports effective delivery in outpatient facilities, is fueling this segment's high growth.

CyberKnife Market Regional Insights

The North American region led the CyberKnife market in 2023, fueled by high adoption levels, sophisticated healthcare infrastructure, and supportive reimbursement policies. The United States alone leads with the largest market share, with more than 100 CyberKnife systems in prominent cancer treatment facilities. Key players like Accuray Inc., coupled with robust investments in robotic radiosurgery, have contributed to further boosting market growth. Europe is close behind, with nations such as Germany, France, and the U.K. increasing their CyberKnife treatment centers because of growing cancer incidence and government support for advanced radiation therapy. CyberKnife is used extensively in these markets for prostate cancer, brain tumors, and lung cancer treatments, further solidifying its market leadership.

Latin America is the region growing at the fastest rate, fueled by mounting cancer incidence, growth in healthcare spending, and increasing access to sophisticated radiation therapy. The region experienced a dramatic increase in cancer incidence, with more than 1.5 million new cancer cases in 2023, providing significant demand for novel treatments. Brazil, Mexico, and Argentina are among the countries investing vigorously in oncology facilities, with government spending as well as private sector investments. Also, medical tourism is driving expansion, with patients from surrounding areas traveling to obtain sophisticated CyberKnife treatment at more affordable prices than in Europe and North America. As awareness and access increase, Latin America is set to experience explosive CyberKnife market growth.

CyberKnife Market Key Players

• Accuray Incorporated – CyberKnife S7, CyberKnife M6

• Varian Medical Systems (a Siemens Healthineers company) – Edge Radiosurgery System, TrueBeam

• Elekta AB – Gamma Knife Icon, Versa HD

• Brainlab AG – Novalis Radiosurgery, ExacTrac Dynamic

• ViewRay, Inc. – MRIdian Linac

• RefleXion Medical – RefleXion X1

• Mitsubishi Heavy Industries, Ltd. – Vero4DRT

• Zap Surgical Systems – ZAP-X Gyroscopic Radiosurgery

• IBA (Ion Beam Applications S.A.) – ProteusONE, ProteusPLUS

• Hitachi, Ltd. – Proton Therapy System

Recent Developments in the CyberKnife Market

• In Jan 2025, Accuray Incorporated received approval from China’s National Medical Products Administration (NMPA) for its Radixact SynC and CyberKnife S7 Systems, expanding its product portfolio in the country. This approval enables advanced radiation therapy solutions, including the first clearance for ClearRT kVCT imaging and Synchrony real-time adaptive delivery on the Radixact System.

• In Aug 2024, Apollo Cancer Centre (ACC), Bengaluru, launched South Asia’s first CyberKnife S7 FIM Robotic Radiosurgery System, revolutionizing cancer and tumor treatment. In collaboration with Accuray, ACC has also introduced the CyberKnife Academia, providing advanced radiosurgery training for medical professionals across South Asia and India.